重新思考小细胞肺癌的治疗策略：从 SKYSCRAPER-02 研究中的替雷利珠单抗中获得的经验教训。
Rethinking strategies in SCLC: Lessons learned from tiragolumab in the SKYSCRAPER-02 study.
机构信息
Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Laboratory of Translational Genomics and Targeted therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.
Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Laboratory of Translational Genomics and Targeted therapies in Solid Tumors, IDIBAPS, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain.
出版信息
Med. 2024 Apr 12;5(4):281-284. doi: 10.1016/j.medj.2024.02.001.
The addition of tiragolumab, an anti-TIGIT inhibitor, to chemotherapy plus atezolizumab demonstrated promising early results for lung cancer. Unfortunately, the phase 3 study SKYSCRAPER-02 did not confirm the anticipated benefit of tiragolumab combination in recalcitrant small-cell lung cancer, reiterating the need for a more accurate population selection in clinical trials.
替雷利珠单抗联合化疗和阿替利珠单抗治疗肺癌的早期结果令人鼓舞。然而，令人遗憾的是，SKYSCRAPER-02 期临床试验并未证实替雷利珠单抗联合方案在难治性小细胞肺癌中具有预期获益，这再次强调了临床试验中需要更准确地选择人群。
Zotero 插件